Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, TKI, and TACE in Unresectable HCC (FRONT-2)
NCT06232759Phase 2Completed
- Sponsor
- Guangxi Medical University
- Start
- Apr 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Guangxi Medical University. Primary endpoint: Progression-Free Survival at 1 year. Started Apr 2022; status: completed.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06232759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232759.